Effects of Mitiglinide, a Short-Acting Insulin Secretagogue, on Daily Glycemic Variability and Oxidative Stress Markers in Japanese Patients with Type 2 Diabetes Mellitus
- First Online:
- 104 Downloads
Background and Objective
The objective of this study was to clarify the effects of mitiglinide on daily glycemic variability and oxidative stress markers in outpatients with type 2 diabetes mellitus that is insufficiently controlled by diet and/or non-insulin secretagogues.
We enrolled 24 patients with type 2 diabetes whose glycemic control had been suboptimal [i.e. glycosylated hemoglobin (HbA1c) ≥6.9 %]. The patients were treated with mitiglinide 10 mg three times daily for 16 weeks. If their glycemic control was not improved at week 8, the dose of mitiglinide was increased to 20 mg three times daily. Daily glycemic variability was assessed by 7-point self-monitoring of blood glucose for 2 days, and standard deviation (SD), M value, and mean of daily differences (MODD) were calculated. Oxidative stress was assessed by oxidized low-density lipoprotein, pentosidine, urinary 8-iso-prostaglandin F2alpha, and urinary 8-hydroxydeoxy guanosine.
After 16 weeks of mitiglinide treatment, the HbA1c level was significantly decreased (mean ± SD, 7.4 ± 0.7 to 6.8 ± 0.5 %, P < 0.0001). Postprandial glucose excursion and glycemic variability were also significantly improved after mitiglinide treatment (all P < 0.05). The reductions in SD, M value, and MODD were 17, 50, and 48 %, respectively. There was a significant positive correlation between the change in HbA1c and change in SD during the study (r = 0.454, P = 0.03). There were no significant changes in oxidative stress markers.
The present study supports the notion that mitiglinide improves postprandial glucose excursion and HbA1c level in patients with type 2 diabetes. In addition, we demonstrated that mitiglinide also effectively improves daily glycemic variability. The effect of mitiglinide on oxidative stress needs further investigation.
- 4.DECODA Study Group, International Diabetes Epidemiology Group. Cardiovascular risk profile assessment in glucose-intolerant Asian individuals—an evaluation of the World Health Organization two-step strategy: the DECODA study (Diabetes Epidemiology: Collaborative Analysis of Diagnostic Criteria in Asia). Diabet Med. 2002;19:549–57.CrossRefGoogle Scholar
- 5.Cavalot F, Petrelli A, Traversa M, et al. Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women: lessons from the San Luigi Gonzaga Diabetes Study. J Clin Endocrinol Metab. 2006;91:813–9.PubMedCrossRefGoogle Scholar
- 15.Ohnota H, Koizumi T, Tsutsumi N, et al. Novel rapid- and short-acting hypoglycemic agent, a calcium(2s)-2-benzyl-3-(cis-hexahydro-2-isoindolinylcarbonyl) propionate (KAD-1229) that acts on the sulfonylurea receptor: comparison of effects between KAD-1229 and gliclazide. J Pharmacol Exp Ther. 1994;269:489–95.PubMedGoogle Scholar
- 23.Saisho Y, Shimada A, Kawai T, et al. Effectiveness of switching from mitiglinide 30 mg or nateglinide 270 mg daily to mitiglinide 60 mg daily on glycemic control and body weight in type 2 diabetic patients. J New Rem Clin. 2010;59:950–9.Google Scholar